Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort Study

Abstract Introduction Atopic dermatitis (AD) is a chronic inflammatory skin condition that significantly affects the quality of life (QoL). Lebrikizumab, a biologic drug targeting interleukin-13, demonstrated efficacy and safety in clinical trials. However, real-world data remain limited, largely re...

Cijeli opis

Bibliografski detalji

Glavni autori:	Gianluca Avallone, Andrea Bombelli, Luigi Gargiulo, Caterina Foti, Ilaria Trave, Mariateresa Rossi, Elisabetta Magnaterra, Flavia Pigliacelli, Piergiorgio Malagoli, Serena Giacalone, Antonio Portarapillo, Cataldo Patruno, Natale Schettini, Laura Bonzano, Elena Pezzolo, Camilla Chello, Niccolò Gori, Giovanna Brunasso, Federica Veronese, Michela Ortoncelli, Ersilia Tolino, Alan Azzolini, Francesco Bellinato, Katharina Hansel, Eugenia Veronica Di Brizzi, Carlotta Gurioli, Maria Esposito, Roberta Giuffrida, Francesca Barei, Paolo Calzari, Anna Graziella Burroni, Massimo Gola, Maria Mariano, Maria Concetta Fargnoli, Maddalena Napolitano, Teresa Grieco, Ketty Peris, Paola Savoia, Simone Ribero, Giampiero Girolomoni, Luca Stingeni, Anna Balato, Antonio Costanzo, Angelo Valerio Marzano, Alessandra Narcisi, Silvia Mariel Ferrucci
Format:	Artigo
Jezik:	Inglês
Izdano:	Adis, Springer Healthcare 2025-10-01
Serija:	Dermatology and Therapy
Teme:	Biologics Monoclonal antibodies IL-13 inhibitor Skin disease Atopic dermatitis Lebrikizumab
Online pristup:	https://doi.org/10.1007/s13555-025-01550-8
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!